September 6, 2016
PureTech gets grant for third U.S. patent for methods of treating infectious and allergic diseases
PureTech gets grant for third U.S. patent for methods of treating infectious and allergic diseases
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
August 25, 2016
Positive Phase III EXPAND study for Novartis
Positive Phase III EXPAND study for Novartis
July 29, 2016
Sanofi reports net income €1,158m, down 11.1%
“Second quarter financial performance was in-line with expectations.” – Olivier Brandicourt, Sanofi CEO
July 25, 2016
Faron and Abzena in cancer medicine Clevegen manufacture deal
Faron and Abzena in cancer medicine Clevegen manufacture deal
July 8, 2016
Vernalis completes its CCP-08 pivotal bioavailability studies
Vernalis has today announced the completion of the CCP-08 pivotal multiple-dose comparative bioavailability study.
July 8, 2016
Allergy Therapeutics Acarovac Plus one year study published
Allergy Therapeutics Acarovac Plus one year study published
July 8, 2016
PureTech Health introduces new members to its Scientific Advisory Board
PureTech Health has introduced new members to its Scientific Advisory Board
July 4, 2016
English Court to consider Premaitha’s defence on Illumia filed case after hearing scheduled for July 2017
English Court to consider Premaitha’s defence after hearing scheduled for July 2017
July 1, 2016
AstraZeneca, LEO Pharma agree on Trolakinumab global rights deal
AstraZeneca has entered into an agreement with LEO Pharma A/S (LEO Pharma), a specialist in dermatology care, for the global licence to tralokinumab in skin diseases. As explained by AstraZeneca, Tralokinumab is a potential new medicine (an anti-IL-13 monoclonal antibody) that has completed a Phase IIb trial for the treatment of patients with atopic dermatitis, an inflammatory skin disease resulting in itchy, red, swollen and cracked skin.
April 8, 2016
Allergan and Heptares team up for novel treatments in Alzheimer’s
Allergan and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation have entered into an agreement under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer’s disease.